We are live on ! Find out more
ATHE

Alterity Therapeutics
ATHE

11 hedge funds and large institutions have $442K invested in Alterity Therapeutics in 2017 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 4 increasing their positions, 0 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

29% more capital invested

Capital invested by funds: $342K → $442K (+$100K)

0% less ownership

Funds ownership: 0% → 0% (-0%)

35% less funds holding

Funds holding: 17 → 11 (-6)

83% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 6

Holders
11
Holders Change
-6
Holders Change %
-35.29%
% of All Funds
0.27%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
4
Reduced
–
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$20.3K
2
UBS Group
UBS Group
Switzerland
+$7.42K
3
AG
Advisor Group
Arizona
+$4.73K
4
Bank of America
Bank of America
North Carolina
+$1.56K
5
NFG
Next Financial Group
Texas
+$1.37K

Top Sellers

Rank Fund Capital Flow
1
Deutsche Bank
Deutsche Bank
Germany
-$45.8K
2
Citadel Advisors
Citadel Advisors
Florida
-$38K
3
VKH
Virtu KCG Holdings
New York
-$38K
4
Renaissance Technologies
Renaissance Technologies
New York
-$27K
5
TRCT
Tower Research Capital (TRC)
New York
-$1K

ATHE Hedge Fund Activity: Q1 2017 in Review

11 of the 4,018 institutional investors tracked by Wall St. Rank reported a position in Alterity Therapeutics (ATHE) for Q1 2017, worth a combined $442K — up 29% from $342K a quarter earlier.

Sellers outnumbered buyers: 6 funds closed out of ATHE and 1 opened new positions — a net loss of 5 holders — while 0 trimmed existing stakes and 4 added.

The largest buyer was Morgan Stanley, adding an estimated $20.3K. The largest seller was Deutsche Bank, exiting entirely with an estimated $45.8K sold.

  • 11 institutional investors held Alterity Therapeutics (ATHE) as of Q1 2017, down from 17 in Q4 2016.
  • Funds reported $442K of Alterity Therapeutics stock for Q1 2017, up 29% quarter-over-quarter.
  • 1 fund opened new Alterity Therapeutics positions in Q1 2017 and 6 closed out, a net change of -5 holders.
  • The largest Alterity Therapeutics buyer in Q1 2017 was Morgan Stanley, an estimated $20.3K added.
  • The largest Alterity Therapeutics seller in Q1 2017 was Deutsche Bank, an estimated $45.8K sold.

Based on aggregated 13F filings for Q1 2017.